A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07707167 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

LA HNSCC

Interventions

DRUG: Pucotenlimab
DRUG: Becotatug vedotin
RADIATION: Radiotherapy

Sponsor

Jiangsu Cancer Institute & Hospital